Status:
COMPLETED
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
Lead Sponsor:
OPKO Health, Inc.
Conditions:
Chronic Hepatitis C
Hepatitis, Viral, Human
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and efficacy of repeated intravenous infusions of EMZ702 in combination with pegylated interferon and ribavirin in patients with chronic hepatitis C g...
Detailed Description
In this study, 28 patients with chronic hepatitis C genotype 1 who have failed previous treatment with pegylated interferon plus ribavirin will be treated. The study treatment will consist of the same...
Eligibility Criteria
Inclusion
- Hepatitis C virus (HCV) genotype 1
- Previous therapy with pegylated interferon and ribavirin
- Documented previous treatment failure
Exclusion
- Hepatic dysfunction
- Coinfection with hepatitis B or HIV
- Other unrelated liver diseases
- Liver cancer
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00230854
Start Date
August 1 2005
End Date
July 1 2007
Last Update
October 18 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
L.H.S.C. University Campus
London, Ontario, Canada, N6A 5A5
2
Ottawa Hospital
Ottawa, Ontario, Canada